COMPANY:

Protean BioDiagnostics

"Nanostics...and Protean BioDiagnostics...announced their partnership to provide CDX Prostate in the United States....CDX Prostate uses biological data, clinical information, and AI-powered learning models to generate a risk score for aggressive prostate cancer, marking a significant advancement in prostate cancer screening. It provides critical support to men and their healthcare providers in making more informed decisions about whether to proceed with a biopsy following a high prostate-specific antigen (PSA) test result or an abnormal Digital Rectal Exam (DRE)."

"Protean BioDiagnostics is proud to announce its partnership with Travera. As one of Travera's first Center of Excellence, the partnership marks the launch of an opportunity that provides patients with advanced carcinoma a functional profile of their cancer cells. Advanced carcinoma patients often have clinically indicated biopsies or malignant fluid drained to provide symptomatic relief. Travera's unique technology takes advantage of this tissue or fluid to screen the response of the live tumor cells against approved anti-cancer therapies."

"ChromaCode, Inc....today announced a strategic partnership with Protean BioDiagnostics Inc...This partnership's goal is to introduce a non-small cell lung cancer (NSCLC) assay, based on ChromaCode's state-of-the-art High Definition PCR (HDPCR™) multiplexing technology, via an early access program....The ultimate goal of the strategic partnership between ChromaCode and Protean is to extend the benefits of affordable and easily accessible assays that ensure rapid and precise diagnoses to a diverse range of patients in both Florida and the rest of the USA."

"Spesana...has announced an agreement with Protean BioDiagnostics. This new agreement will amplify Protean's mission to rapidly deploy innovative and clinically impactful tests...As a part of Spesana's Precision Medicine Platform, Protean will be supported by efficient ordering, tracking, and reporting workflows in addition to education and communication capabilities."

"Dr. Magliocco will be presenting a special lecture at Future Genomics 2023 on the roles of genomic testing technology for improving the diagnosis and treatment of cancer patients...Topics will include: Implementing WES as part of the Protean MAPS™ precision oncology system..."

"Arima Genomics, Inc...announced an agreement to make an Arima next-generation sequencing-based test available to clinicians for patient management through Protean BioDiagnostic’s CLIA-certified, CAP-accredited laboratory in Orlando, Florida. The new testing service, using Arima’s novel genomic technology, will identify clinically actionable gene fusions in tumor tissue from patients with cancer, and is anticipated to be available for order in the first half of 2023."

"...presenting two case studies this year at AMP 22, on the use of DelPHI, Protean MAPS, and Navify Digital Tools for the timely diagnosis and/or treatment of cancer...systematic approach that combines molecular testing with digital decision support tools to diagnose a child’s ES and identify viable therapy options."

"Protean BioDiagnostics will be presenting a case study this year at AMP 22, on the topic of the importance of precision medicine in uncovering a patient’s true diagnosis...This is a case study that highlights the power of Protean to catch a liver carcinoma misdiagnosis using pathology review, comprehensive in-house molecular testing, and virtual molecular tumor boards."

"Protean BioDiagnostics and Qualisure Diagnostics Inc. announced...that both companies have entered into a strategic partnership to launch a novel diagnostic test for thyroid cancer. Thyroid GuidePx® is the first genomic classifier for papillary thyroid cancer, designed to assist clinicians treating thyroid cancer in making treatment decisions."

"Protean BioDiagnostics to present on the use of optical genome mapping and NGS to understand epitheliod sarcoma in a pediatric patient...Combining traditional next generation sequencing with optical genome mapping presents a robust picture of the precise genomic alterations. Evidence of these specific structural alterations combined with immunohistochemistry provides clinically relevant variants for genetic disease, which can be utilized to identify actionable targets for therapy, and more optimal outcome for the patient."

"Protean BioDiagnostics to present on embryonal rhabdomyosarcoma in a pediatric patient...Combining immunohistochemistry, OncoTargets pathway analysis that measures key signaling pathway activity, Follow It liquid biopsy, and structural chromosome aberration analysis by copy number variation uncovered that this patient was eligible for a novel clinical trial containing MEK and PD-L1 checkpoint inhibitors."

"Experts from Protean BioDiagnostics will present ground breaking research focused on identifying the molecular basis of colorectal cancer and how it differs between men and women in America at the AACR 2022 meeting in New Orleans...The findings have implications for designing effective screening and treatments which may need to be adjusted based on the gender of the subject."